Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Carrer de Sant Quintí, 89, 08041 Barcelona, Spain.
Int J Mol Sci. 2023 Jun 18;24(12):10305. doi: 10.3390/ijms241210305.
The interleukin 17 (IL-17) family, a subset of cytokines consisting of IL-17A-F, plays crucial roles in host defence against microbial organisms and the development of inflammatory diseases, including psoriasis (PsO), axial spondyloarthritis (axSpA), and psoriatic arthritis (PsA). IL-17A is the signature cytokine produced by T helper 17 (Th17) cells and is considered the most biologically active form. The pathogenetic involvement of IL-17A in these conditions has been confirmed, and its blockade with biological agents has provided a highly effective therapeutical approach. IL-17F is also overexpressed in the skin and synovial tissues of patients with these diseases, and recent studies suggest its involvement in promoting inflammation and tissue damage in axSpA and PsA. The simultaneous targeting of IL-17A and IL-17F by dual inhibitors and bispecific antibodies may improve the management of Pso, PsA, and axSpA, as demonstrated in the pivotal studies of dual specific antibodies such as bimekizumab. The present review focuses on the role of IL-17F and its therapeutic blockade in axSpA and PsA.
白细胞介素 17（IL-17）家族是由 IL-17A-F 等细胞因子组成的亚群，在宿主防御微生物和炎症性疾病的发展中起着至关重要的作用，包括银屑病（PsO）、轴性脊柱关节炎（axSpA）和银屑病关节炎（PsA）。IL-17A 是 Th17 细胞产生的标志性细胞因子，被认为是最具生物活性的形式。IL-17A 在这些疾病中的发病机制参与已得到证实，其生物制剂的阻断已提供了一种非常有效的治疗方法。IL-17F 在这些疾病患者的皮肤和滑膜组织中也过表达，最近的研究表明它参与了 axSpA 和 PsA 中炎症和组织损伤的促进。双特异性抗体和双抑制剂同时靶向 IL-17A 和 IL-17F，可能会改善 Pso、PsA 和 axSpA 的治疗效果，这在 bimekizumab 等双特异性抗体的关键研究中得到了证明。本综述重点关注 IL-17F 的作用及其在 axSpA 和 PsA 中的治疗阻断。
